Selegiline protects against recognition memory impairment induced by neonatal iron treatment

Experimental Neurology

Volumn 196, Issue 1, 2005, Pages 177-183

  De Lima, Maria Noemia Martins ^a   Laranja, Daniela Comparsi ^a   Caldana, Fábio ^a   Grazziotin, Manoela Michelon ^a   Garcia, Vanessa Athaíde ^a   Dal Pizzol, Felipe ^b   Bromberg, Elke ^a   Schröder, Nadja ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Iron; Neurodegeneration; Neuroprotection; Oxidative stress; Rat; Recognition memory; Selegiline

Indexed keywords

IRON; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; SODIUM CHLORIDE; SORBITOL; WATER;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; MALE; MEMORY DISORDER; NEUROPROTECTION; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; RECOGNITION;

ANIMALS; ANIMALS, NEWBORN; IRON; MALE; MEMORY DISORDERS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); SELEGILINE;

EID: 26244444506     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2005.07.017     Document Type: Article

References (53)

1. A. Barbelivien, L. Nyman, A. Haapalinna, and J. Sirvio Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks Pharmacol. Toxicol. 88 2001 304 312
2. D. Ben-Shachar, R. Ashkenazi, and M.B. Youdim Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats Int. J. Dev. Neurosci. 4 1986 81 88
3. R. Brandeis, M. Sapir, Y. Kapon, G. Borelli, S. Cadel, and B. Valsecchi Improvement of cognitive function by MAO-B inhibitor l-deprenyl in aged rats Pharmacol. Biochem. Behav. 39 1991 297 304
4. M.C. Carrilo, S. Kanai, M. Nokubo, G.O. Ivy, Y. Sato, and K. Kitani (-)Deprenyl increases activities of superoxido dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat Exp. Neurol. 116 1992 286 294
5. G. Cohen, P. Pasik, B. Cohen, A. Leist, C. Mytilineou, and M.D. Yahr Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in monkeys Eur. J. Pharmacol. 106 1984 209 210
6. M.N. De Lima, D.C. Laranja, F. Caldana, E. Bromberg, R. Roesler, and N. Schroder Reversal of age-related deficits in object recognition memory in rats with l-deprenyl Exp. Gerontol. 40 2005 506 511
7. M.N.M. De Lima, M. Polydoro, D.C. Laranja, F. Bonnato, E. Bromberg, J.C.F. Moreira, F. Dal-Pizzol, and N. Schröder Recognition memory impairment and brain oxidative stress induced by postnatal iron administration Eur. J. Neurosci. 21 2005 2521 2528
8. S.L. Dix, and J.P. Aggleton Extending the spontaneous preference test of recognition: evidence of object-location and object-location and object-context recognition Behav. Brain Res. 99 1999 191 200
9. S.N. Dixit, M. Behari, and G.K. Ahuja Effect of selegiline on cognitive functions in Parkinson's disease J. Assoc. Physians India 47 1999 784 786
10. R.A. Floyd, and K. Hensley Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases Neurobiol. Aging 23 2002 795 807
11. A. Fredriksson, N. Schröder, P. Eriksson, I. Izquierdo, and T. Archer Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice Toxicol. Appl. Pharmacol. 159 1999 25 30
12. A. Fredriksson, N. Schröder, P. Eriksson, I. Izquierdo, and T. Archer Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period Dev. Brain Res. 119 2000 65 74
13. K. Fukui, K. Onodera, T. Shinkai, S. Suzuki, and S. Urano Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems Ann. N. Y. Acad. Sci. 928 2001 168 175
14. K. Fukui, N.O. Omoi, T. Hayasaka, T. Shinnkai, S. Suzuki, K. Abe, and S. Urano Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E Ann. N. Y. Acad. Sci. 959 2002 275 284
15. D.L. Gelowitz, and I.A. Paterson Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration Pharmacol. Biochem. Behav. 62 1999 255 262
16. E. Head, J. Hartley, A.M. Kameka, R. Mehta, G.O. Ivy, W.W. Ruehl, and N.W. Milgram The effects of l-deprenyl on spatial short term memory in young and aged dogs Prog. Neuro-psychopharmacol. Biol. Psychiatry 20 1996 515 530
17. K.A. Jellinger The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease Drugs Aging 14 1999 115 140
18. D. Kaur, and J. Andersen Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res. Rev. 3 2004 327 343
19. M. Kiray, N. Uysal, A. Sonmez, O. Acikgoz, and S. Gonenc Positive effects of deprenyl and estradiol on spatial memory and oxidant stress in aged female rat brains Neurosci. Lett. 354 2004 225 228
20. M. Kiray, H.A. Bagriyanik, C. Pekcetin, B.U. Ergur, N. Uysal, D. Ozyurt, and Z. Buldan Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats Physiol. Res. 2005 (May 24, Electronic publication ahead of print)
21. K. Kitani, C. Minami, K. Isobe, K. Maehara, S. Kanai, G.O. Ivy, and M.C. Carrillo Why (-)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects Mech. Ageing Dev. 123 2002 1087 1100
22. M.L. Leret, J.A. San Millán, E. Fabre, R. Gredilla, and G. Barja Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum Toxicology 170 2002 165 171
23. R. Liu, I.Y. Liu, X. Bi, R.F. Thompson, S.R. Doctrow, B. Malfroy, and M. Baudry Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics Proc. Natl. Acad. Sci. U. S. A. 100 2003 8526 8531
24. F.D. Maia, B.S. Pitombeira, D.T. Araujo, G.M. Cunha, and G.S. Viana l-Deprenyl prevents lipid peroxidation and memory deficits produced by cerebral ischemia in rats Cell Mol. Neurobiol. 24 2004 87 100
25. W.R. Martin, F.Q. Ye, and P.S. Allen Increasing striatal iron content associated with normal aging Mov. Disord. 13 1998 281 286
26. W. Maruyama, and M. Naoi Neuroprotection by (-)-deprenyl and related compounds Mech. Ageing Dev. 111 1999 189 200
27. K. Matsubara, T. Senda, T. Uezono, T. Awaya, S. Ogawa, K. Chiba, K. Shimizu, N. Hayase, and K. Kimura l-deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP+, and β-carbolinium: a microdialysis study in rats Neurosci. Lett. 302 2001 65 68
28. C. Mytilineou, P.M. Radcliffe, and C.W. Olanow l-(-)-desmethylselegiline, a metabolite of selegiline [l-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro J. Neurochem. 68 1997 434 436
29. E. Oestreicher, G.J. Sengstock, P. Riederer, C.W. Olanow, A.J. Dunn, and G.W. Arendash Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study Brain Res. 660 1994 8 18
30. Parkinson Study Group Effect of (-)deprenyl on the progression disability in early Parkinson's disease N. Engl. J. Med. 321 1989 1364 1371
31. Parkinson Study Group Effect of tocopherol and (-)deprenyl on the progression of disability in early Parkinson's disease N. Engl. J. Med. 328 1993 176 183
32. I.A. Paterson, A.J. Barber, D.L. Gelowitz, and C. Voll (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells Neurosci. Biobehav. Rev. 21 1997 181 186
33. J.M. Reed, and L.R. Squire Impaired recognition memory in patients with lesions limited to the hippocampal formation Behav. Neurosci. 111 1997 667 675
34. A.J. Roskams, and J.R. Connor Iron, transferrin, and ferritin in the rat brain during development and aging J. Neurochem. 63 1994 709 716
35. N. Schröder, A. Fredriksson, M.R. Vianna, R. Roesler, I. Izquierdo, and T. Archer Memory deficits in adult rats following postnatal iron administration Behav. Brain Res. 124 2001 77 85
36. N. Schröder, S.J. O'Dell, and J.F. Marshall Neurotoxic methamphetamine regimen severely impairs recognition memory in rats Synapse 49 2003 89 96
37. M. Schulzer, E. Mak, and D.B. Calne The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic Ann. Neurol. 32 1992 795 798
38. G.J. Sengstock, C.W. Olanow, R.A. Menzies, A.J. Dunn, and G.W. Arendash Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers J. Neurosci. Res. 35 1993 67 82
39. F. Serrano, and E. Klann Reactive oxygen species and synaptic plasticity in the aging hippocampus Ageing Res. Rev. 3 2004 431 443
40. D.J. Socci, B.M. Crandall, and G.W. Arendash Chronic antioxidant treatment improves the cognitive performance of aged rats Brain Res. 693 1995 88 94
41. W.P. Spooren, P. Waldmeier, and C. Gentsch The effect of a subchronic post-lesion treatment with (-)-deprenyl on the sensitivity of 6-OHDA-lesioned rats to apomorphine and d-amphetamine J. Neural Transm. 106 1999 825 833
42. S. Stoll, U. Hafner, O. Pohl, and W.E. Muller Age-related memory decline and longevity under treatment with selegiline Life Sci. 55 1994 2155 2163
43. Y.P. Tang, E. Shimizu, G.R. Dube, C. Rampon, G.A. Kerchner, M. Zhuo, G. Liu, and J.Z. Tsien Genetic enhancement of learning and memory in mice Nature 401 1999 63 69
44. W.G. Tatton, and R.M. Chalmers-Redman Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration Neurology 47 1996 171 183
45. J.A. Temlett, J.P. Landsberg, F. Watt, and G.W. Grime Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis J. Neurochem. 62 1994 134 146
46. M. Thomas, and J. Jankovic Neurodegenerative disease and iron storage in the brain Curr. Opin. Neurol. 17 2004 437 442
47. J.W. Tretud, and J.W. Langston The effect of (-)deprenyl (selegiline) on the natural history of Parkinson's disease Science 245 1989 519 522
48. L. Yavich, J. Sirvio, E. Heinonen, and P. Riekkinen Sr. The interaction of l-deprenyl and scopolamine on spatial learning/memory in rats J. Neural Transm., Parkinson's Dis. Dement. Sect. 6 1993 189 197
49. M.B. Youdim, and S. Yehuda The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system Cell. Mol. Biol. (Noisy-le-grand) 46 2000 491 500
50. M.B. Youdim, D. Ben-Shachar, and P. Riederer Iron in brain function and dysfunction with emphasis on Parkinson's disease Eur. Neurol. 31 1991 34 40
51. M.B. Youdim, G. Stephenson, and D. Ben Shachar Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28 Ann. N. Y. Acad. Sci. 1012 2004 306 325
52. M.B. Youdim, M. Fridkin, and H. Zheng Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases Mech. Ageing Dev. 126 2005 317 326
53. L. Zecca, M.B. Youdim, P. Riederer, J.R. Connor, and R.R. Crichton Iron, brain ageing and neurodegenerative disorders Nat. Rev., Neurosci. 5 2004 863 873